Side-by-side · Research reference

CJC-1295 (no DAC)vsCrystagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 1HUMAN-REVIEWED15/51 cited

BAnimal-MechanisticHUMAN-REVIEWED12/40 cited

CJC-1295 (no DAC)

Short-acting GHRH · No DAC variant

100 mcgPer doseTeichman 2006

~30 minHalf-lifeIonescu 2006

Phase 1Evidence levelTeichman 2006 Sigalos 2018

SQ · Pre-sleep · 1–2×/day

Crystagen

Khavinson Bioregulator · Immune-Thymic

B-cellPrimary targetСhervyakova 2014

SpleenTissue specificityСhervyakova 2014

AnimalEvidence level

SQ · Protocol variable

01Mechanism of Action

Parameter

CJC-1295 (no DAC)

Crystagen

Primary target

Pituitary GHRH receptorTeichman 2006

B-lymphocytes in splenic tissueСhervyakova 2014

Pathway

GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisTeichman 2006

B-cell activation → Immune modulation during agingСhervyakova 2014

Downstream effect

Pulsatile GH release matching physiological pattern; subsequent IGF-1 elevationIonescu 2006

B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014

Feedback intact?

Yes — short pulse preserves somatostatin negative feedbackIonescu 2006

Unknown — bioregulator mechanism not fully characterized

Origin

Modified human GRF 1-29 with four substitutions (D-Ala²/Gln⁸/Ala¹⁵/Leu²⁷) for protease resistanceTeichman 2006

Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series

Antibody development

Not reported in short-term studies

—

02Dosage Protocols

Parameter

CJC-1295 (no DAC)

Crystagen

Standard dose

100 mcg per injectionTeichman 2006

Often paired with ipamorelin in same syringe.

Not standardized — variable protocols

Russian bioregulator literature does not specify unified human dosing.

Frequency

1–2× daily (pre-sleep ± morning)

Unknown — bioregulator protocols variable

Lower / starter dose

50 mcg per dose

—

Evidence basis

Phase 1 (CJC-1295 with DAC); analog dataTeichman 2006 Ionescu 2006

No-DAC variant is less studied directly; PK extrapolated from native GHRH.

Animal / mechanistic

Duration

8–12 weeks on / 4 off (anecdotal)

Unknown — chronic administration presumed in animal models

Reconstitution

Bacteriostatic water

—

Timing

Pre-sleep + fasted preferred

—

Half-life

~30 minIonescu 2006

Short pulse vs CJC-1295-DAC (~8 days). Choose no-DAC for pulsatile, DAC for sustained.

Not reported

Route

—

Subcutaneous (presumed from bioregulator class)

04Side Effects & Safety

Parameter

CJC-1295 (no DAC)

Crystagen

Injection site reaction

Erythema, mild pruritus

—

Flushing / headache

Common transient effect

—

Cortisol elevation

Minimal at standard doses

—

Prolactin elevation

Minimal

—

Glucose intolerance

Possible at high cumulative doses

—

IGF-1 elevation

Dose-dependent; monitor with chronic use

—

Cancer risk

Contraindicated in active malignancy (GH/IGF-1 axis)

—

Pregnancy / OB

Avoid

—

Published adverse events

—

None reported in available animal literature

Human safety data

—

Absent — no controlled human trials identified

Autoimmune considerations

—

Theoretical concern with B-cell modulators in predisposed individuals

Absolute Contraindications

CJC-1295 (no DAC)

·Active malignancy or cancer history
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

Crystagen

·Active autoimmune disease (theoretical)

Relative Contraindications

CJC-1295 (no DAC)

·Untreated diabetes
·Severe insulin resistance

Crystagen

·Pregnancy / lactation (no data)
·Active B-cell malignancies

05Administration Protocol

Parameter

CJC-1295 (no DAC)

Crystagen

1. Reconstitution

Add 2 mL bacteriostatic water to 2 mg vial → 1 mg/mL = 100 mcg per 0.1 mL. Roll gently.

Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.

2. Injection site

Subcutaneous, abdomen or thigh. Rotate sites.

Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.

3. Timing

Pre-sleep preferred. Often combined with ipamorelin in the same syringe.

Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.

4. Storage

Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.

Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.

5. Needle

29–31G, 4–8 mm insulin syringe.

—

06Stack Synergy

CJC-1295 (no DAC)

+ Ipamorelin

Strong

View Ipamorelin →

CJC-1295 (no DAC) and ipamorelin are the canonical "GHRH + GHRP" dual-axis stack at physiological timing. Both peak within 30 min and clear within 2 hours, producing a sharp, high-amplitude GH pulse closely resembling natural physiology. Preferred over the CJC-1295-DAC + ipamorelin stack when pulsatility (vs sustained elevation) is the goal.

CJC-1295 (no DAC): 100 mcg SQ · pre-sleep
Ipamorelin: 200–300 mcg SQ · same injection
Primary benefit: Pulsatile GH stimulation, recovery, body composition

Teichman 2006 Raun 1998

Crystagen

+ Vilon

Multi-pathway

View Vilon →

Vilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.

Crystagen: Dose unknown · SQ
Vilon: Dose unknown · SQ
Frequency: Protocol variable
Primary benefit: Broader thymic-immune coverage (T-cell + B-cell)

Сhervyakova 2014